In a reversal, the FDA is reconsidering its decision to end the shortage status of tirzepatide, after a recent lawsuit and intense public pressure, The Washington Post reported Oct. 21.

Lilly has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, ...

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...

Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering ...

Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its ...

A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like ...

MangoRx remains committed to its mission and plans to continue to enhance patient care by offering new and innovative solutions while striving to comply with federal, state and local regulatory ...

Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products ...

You've probably heard about the dramatic weight loss that can happen when you take Ozempic or Wegovy. These medications mimic ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 568.82% and ...

The Washington Post reports that intense public backlash and a lawsuit led the FDA to reconsider its declaration, made two weeks ago, that the shortage of weight-loss drugs Mounjaro and Zepbound is ...